Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Biogen Investigates Aduhelm Patient's Death

Published 11/09/2021, 02:48 PM
Updated 11/09/2021, 02:51 PM
© Reuters

By Sam Boughedda

Investing.com — Barring a reversal, Biogen Inc (NASDAQ:BIIB) stock is set to close down for the third consecutive day after it was reported that the company is investigating the death of a 75-year-old patient after he recently received the company's Aduhelm Alzheimer's drug.

According to a report in The Wall Street Journal, the patient was hospitalized and diagnosed with brain swelling after taking the recently approved drug.

Biogen set it is not yet known if the brain swelling was related to Aduhelm.

"All the recently published cases related to Aduhelm are under careful review as well as medical evaluation, including the fatal case of a 75-year-old patient whose cause of death remains under investigation and who was diagnosed during hospitalization with cerebral edema thought to be ARIA-E," the company was quoted as saying.

Biogen shares are currently down 1.3% on Tuesday, adding to Monday's more than 2% decline.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.